|
Pharmexcil opens dialogue with US on strengthening trade facilitation, market access for Indian pharmaproducts
|
|
Shardul Nautiyal, Mumbai
July 02 , 2025
|
|
|
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has opened a focussed dialogue with the US on strengthening trade facilitation, regulatory alignment, and market access for Indian pharmaceutical products, as part of the meeting held at the Embassy of India (EOI), USA.
Raja Bhanu, director general, Pharmexcil recently had discussions with Dr. Ajay Kumar, Minister (Commerce) EOI, USA to address key issues related to pharmaceutical exports.
Pharmexcil also had discussions with Akhilesh Singh, Counsellor, Commerce, Indian Embassy, USA and discussed matter pertaining to tariffs and impact on the pharmaceutical industry. This was focused on strengthening trade frameworks, addressing regulatory challenges and enhancing India’s global pharmaceutical presence.
As India’s pharmaceutical exports continue to grow, such engagements are a relevant and welcome developments reinforcing trade partnerships and ensuring sustainable industry expansion.
According to Pharmexcil, nearly one-third of India's pharmaceutical exports go to the US, with exports rising by 16 percent to approximately USD 9 billion in the fiscal year of 2024-25. The US pharmaceutical market size was estimated at USD 634.32 billion in 2024 and is expected to grow at a CAGR of 5.72% from 2025 to 2030, to reach an estimated value of USD 883.97 billion by 2030.
The discussions aimed to enhance bilateral cooperation, streamline export processes, and address challenges faced by Indian exporters in the evolving global pharmaceutical landscape. “This engagement underscores India's commitment to ensuring compliance with international standards while reinforcing its position as a reliable supplier of high quality pharmaceutical products worldwide,” according to trade experts.
In today’s scenario, supply chains are globally interconnected. China, India, Ireland, and a few other European countries supply a large fraction of generic and branded medications to the United States as either finished drug products or their intermediary ingredients. Imposing tariffs will likely disrupt the movement of essential raw materials, active pharmaceutical ingredients (APIs), and finished medications. In the near term, disruptions will likely increase costs, delay access to treatments, and trigger shortages, especially for critical generic medicines with already tenuous supply, such as antibiotics, intravenous fluids, sterile injectables (e.g., epinephrine, heparin), and infused cancer therapies.
Major factors towards driving exports growth to the US are increased focus on healthcare and advancements in medicine, streamlined regulatory processes for export licensing, enhanced manufacturing efficiency, collaborations with international distributors and favourable financial conditions boosting investments.
Imports have also been playing a crucial role in ensuring a diverse and uninterrupted supply of pharmaceutical products. Encouraging imports, therefore, ensures consistent supply of essential medicines.
Besides this, experts pinpoint that other motivating factors suggested are that competitive pricing offers expanding options to optimize costs, innovation access to introduce advanced formulations from global markets and resilience against disruptions to mitigate risks from local production constraints.
|
|
|
|
|
|
|
|
TOPICS
|
Shanghai-based Hualian Pharmaceutical Machinery Company Limited, a family-run enterprise with roots going back to 1986, ...
|
|
|
|
|